Special Issue

The Therapeutic Potential of Cannabidiol

Message from the Guest Editors

Cannabidiol (CBD), a non-psychoactive phytocannabinoid derived from Cannabis sativa, has recently attracted significant attention in both clinical and basic science communities due to its potential therapeutic benefits. Evidence suggests that CBD may offer promising effects in pain modulation, muscle relaxation, neuroprotection, and the management of inflammation—without the psychotropic effects associated with THC. This Special Issue aims to explore and consolidate current research on the therapeutic properties of cannabidiol, with a particular focus on its application in conditions such as orofacial pain, temporomandibular disorders, bruxism, and neuromuscular dysfunction. We invite original research papers, clinical trials, systematic reviews, and short communications that investigate the efficacy, mechanisms of action, safety profile, pharmacological properties, and pharmaceutical formulations of CBD. We also encourage submissions that examine interdisciplinary or biopsychosocial approaches incorporating cannabidiol as part of a broader therapeutic strategy. We look forward to your valuable contributions to this timely and rapidly developing field.

Guest Editors

Dr. Karolina Walczyńska-Dragon

Department of Temporomandibular Disorders, Medical University of Silesia in Katowice, 41-800 Zabrze, Poland

Dr. Anna Kurek-Górecka

Department of Microbiology and Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 19 Jordana Street, 41-800 Zabrze, Poland

Deadline for manuscript submissions

25 May 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/240859

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

